Clinical Trial Update: Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a combination of demethylating agents with venetoclax to prevent relapse in patients with high-risk T-cell acute lymphobl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• Demethylating agents (class)
• Venetoclax (venetoclax)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Phase 2 | Status: RECRUITING